AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 156 filers reported holding AIMMUNE THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.54 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $99,000 | +106.2% | 2,879 | 0.0% | 0.00% | – |
| Q2 2020 | $48,000 | +14.3% | 2,879 | 0.0% | 0.00% | – |
| Q1 2020 | $42,000 | -56.2% | 2,879 | 0.0% | 0.00% | – |
| Q4 2019 | $96,000 | -15.0% | 2,879 | -46.9% | 0.00% | – |
| Q2 2019 | $113,000 | -6.6% | 5,426 | 0.0% | 0.00% | – |
| Q1 2019 | $121,000 | +59.2% | 5,426 | +63.7% | 0.00% | – |
| Q4 2018 | $76,000 | -16.5% | 3,315 | 0.0% | 0.00% | – |
| Q3 2018 | $91,000 | +2.2% | 3,315 | 0.0% | 0.00% | – |
| Q2 2018 | $89,000 | -16.0% | 3,315 | 0.0% | 0.00% | – |
| Q1 2018 | $106,000 | -15.2% | 3,315 | 0.0% | 0.00% | – |
| Q4 2017 | $125,000 | +54.3% | 3,315 | 0.0% | 0.00% | – |
| Q3 2017 | $81,000 | +19.1% | 3,315 | 0.0% | 0.00% | – |
| Q2 2017 | $68,000 | -5.6% | 3,315 | 0.0% | 0.00% | – |
| Q1 2017 | $72,000 | +5.9% | 3,315 | 0.0% | 0.00% | – |
| Q4 2016 | $68,000 | – | 3,315 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,295,712 | $47,524,000 | 3.98% |
| Samsara BioCapital, LLC | 232,571 | $3,354,000 | 1.93% |
| Eventide Asset Management | 3,851,000 | $55,531,000 | 1.80% |
| Burrage Capital Management LLC | 112,546 | $1,609,000 | 1.58% |
| Avidity Partners Management LP | 408,000 | $5,883,000 | 0.81% |
| RICE HALL JAMES & ASSOCIATES, LLC | 982,484 | $14,167,000 | 0.79% |
| Bullseye Asset Management LLC | 43,374 | $626,000 | 0.75% |
| Nantahala Capital Management | 1,005,302 | $14,496,000 | 0.54% |
| ARMISTICE CAPITAL, LLC | 600,000 | $8,652,000 | 0.54% |
| Values First Advisors, Inc. | 27,042 | $389,947 | 0.47% |